Objective:To investigate the expression of E-cadherin (E-cad) in cervical squamous cell carcinoma and its prognostic significance.Methods:The clinical data of 80 patients with cervical squamous cell carcinoma who received radical radiotherapy in People's Hospital of Xinjiang Uyghur Autonomous Region from January 2013 to October 2016 were retrospectively analyzed. The expression of E-cad protein in cancer tissues was detected by using automatic immunohistochemistry and the relationship between its expression and clinicopathological features of patients with cervical squamous cell carcinoma was analyzed. Kaplan-Meier method was used to make survival analysis, and Cox proportional risk model was used to analyze the factors affecting the prognosis of patients.Results:Among 80 patients, 30 (37.5%) cases died, the median progression-free survival (PFS) time was 43.7 months (95% CI 46.3-62.4 months), and the median overall survival (OS) time was not reached. The low expression rate of E-cad was 53.75% (43/80). The low expression rate of E-cad in low differentiated patients was higher than that in middle and high differentiated patients [75.0% (21/28) vs. 42.3% (22/52), χ2 = 7.83, P = 0.005]; the low expression rate of E-cad in patients with International Federation of Gynecology and Obstetrics (FIGO) stage Ⅲ A-Ⅲ B was higher than that in those with stage Ⅰ B2-Ⅱ B [65.9% (31/47) vs. 36.5% (12/33), χ2 = 6.83, P = 0.012]. The PFS and OS of patients with low expression of E-cad were worse than those of patients with high expression of E-cad, and the differences were statistically significant ( χ2 = 5.51, P = 0.018; χ2 = 7.48, P = 0.006). Multivariate Cox regression analysis showed that E-cad low expression was an independent risk factor for PFS and OS in patients with cervical squamous cell carcinoma ( HR = 1.836, 95% CI 1.023-3.297, P < 0.05; HR = 2.439, 95% CI 1.091-5.698, P < 0.05). Conclusion:The low expression of E-cad is an important influencing factor for the poor prognosis of patients with cervical squamous cell carcinoma.